Search

Your search keyword '"Mann, Grace"' showing total 48 results
Start Over Author "Mann, Grace"
48 results on '"Mann, Grace"'

1. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study.

Author

Borazanci, Erkut, Bahary, Nathan, Chung, Vincent, Huyck, Timothy, Kio, Ebenezer, Chiorean, Elena, Skeel, Roland, Alese, Olatunji, Cardin, Dana, Fountzilas, Christos, Hanna, Wahid, Leal, Alexis, Lee, Valerie, Noonan, Anne, Philip, Philip, Wainberg, Zev, Pashova, Hristina, Mann, Grace, and Oberstein, Paul

Subjects
PDAC, metastatic pancreatic cancer, nab-paclitaxel, relacorilant, Humans, Paclitaxel, Albumins, Female, Male, Carcinoma, Pancreatic Ductal, Middle Aged, Aged, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adult, Neoplasm Metastasis, Aged, 80 and over
Abstract

BACKGROUND: Modulation of glucocorticoid receptor (GR) activity in tumor cells enhances chemotherapy efficacy. We evaluated the selective GR modulator relacorilant plus nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who had received at least 2 prior therapy lines. PATIENTS AND METHODS: In this open-label, single-arm, phase III study, patients received once-daily oral relacorilant (100 mg, titrated to 150 mg in 25 mg increments/cycle) and nab-paclitaxel (80 mg/m2) on days 1, 8, and 15 of 28-day cycles. The primary efficacy endpoint was objective response rate (ORR) by blinded independent central review. Progression-free survival (PFS), overall survival (OS), target gene modulation, and safety were also assessed. RESULTS: Of 43 patients enrolled, 31 were evaluable for ORR (12 did not reach first postbaseline radiographic assessment). An interim analysis to assess whether ORR was ≥10% showed no confirmed responses and the study was discontinued. Two (6.5%) patients attained unconfirmed partial responses and 15 (48.4%) had stable disease. Fourteen of 31 (45.2%) patients had reductions in target lesion size, despite prior nab-paclitaxel exposure in 12 of the 14. Median PFS and OS were 2.4 months (95% CI, 1.4-4.2) and 3.9 months (95% CI, 2.8-4.9), respectively. The most common adverse events were fatigue and nausea. RNA analysis confirmed that relacorilant plus nab-paclitaxel suppressed 8 cortisol target genes of interest. CONCLUSION: Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.

Published
2024

3. Abstract 3434: Selective glucocorticoid receptor modulation reveals a new role for CLEC10A in patients with solid tumors

Author

Colombo, Nicoletta, primary, Van Gorp, Toon, additional, Matulonis, Ursula A., additional, Oaknin, Ana, additional, Grisham, Rachel N., additional, Provencher, Diane, additional, Fleming, Gini F., additional, Olawaiye, Alexander B., additional, Borazanci, Erkut H., additional, Szmulewitz, Russell Z., additional, Wadekar, Subhagya A., additional, Mann, Grace, additional, Hunt, Hazel J., additional, Greenstein, Andrew E., additional, and Lorusso, Domenica, additional

Published
2023
Full Text
View/download PDF

4. Supplementary Figure S2 from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

5. Data from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Data from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, primary, Stricker, Thomas, primary, Hyman, David M., primary, Blauvelt, Natalie, primary, Bedard, Philippe L., primary, Meric-Bernstam, Funda, primary, Punglia, Rinaa S., primary, Schrag, Deborah, primary, Lepisto, Eva M., primary, Andre, Fabrice, primary, Smyth, Lillian, primary, Dogan, Semih, primary, Yu, Celeste, primary, Wathoo, Chetna, primary, Levy, Mia, primary, Eli, Lisa D., primary, Xu, Feng, primary, Mann, Grace, primary, Lalani, Alshad S., primary, Ye, Fei, primary, Micheel, Christine M., primary, and Arnedos, Monica, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, primary, Stricker, Thomas, primary, Hyman, David M., primary, Blauvelt, Natalie, primary, Bedard, Philippe L., primary, Meric-Bernstam, Funda, primary, Punglia, Rinaa S., primary, Schrag, Deborah, primary, Lepisto, Eva M., primary, Andre, Fabrice, primary, Smyth, Lillian, primary, Dogan, Semih, primary, Yu, Celeste, primary, Wathoo, Chetna, primary, Levy, Mia, primary, Eli, Lisa D., primary, Xu, Feng, primary, Mann, Grace, primary, Lalani, Alshad S., primary, Ye, Fei, primary, Micheel, Christine M., primary, and Arnedos, Monica, primary

Published
2023
Full Text
View/download PDF

9. Data from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, primary, Stricker, Thomas, primary, Hyman, David M., primary, Blauvelt, Natalie, primary, Bedard, Philippe L., primary, Meric-Bernstam, Funda, primary, Punglia, Rinaa S., primary, Schrag, Deborah, primary, Lepisto, Eva M., primary, Andre, Fabrice, primary, Smyth, Lillian, primary, Dogan, Semih, primary, Yu, Celeste, primary, Wathoo, Chetna, primary, Levy, Mia, primary, Eli, Lisa D., primary, Xu, Feng, primary, Mann, Grace, primary, Lalani, Alshad S., primary, Ye, Fei, primary, Micheel, Christine M., primary, and Arnedos, Monica, primary

Published
2023
Full Text
View/download PDF

10. Phase 1 efficacy and pharmacodynamic results of exicorilant + enzalutamide in patients with metastatic castration-resistant prostate cancer.

Author

Morris, Michael J., primary, Linch, Mark David, additional, Crabb, Simon J., additional, Beer, Tomasz M., additional, Heath, Elisabeth I., additional, Gordon, Michael S., additional, De Bono, Johann S., additional, Pashova, Hristina I, additional, Tudor, Iulia Cristina, additional, Greenstein, Andrew E, additional, Mann, Grace, additional, and Liu, Glenn, additional

Published
2023
Full Text
View/download PDF

12. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler, Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, and Solit, David B.

Published
2019
Full Text
View/download PDF

13. Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE

Author

LeNoue-Newton, Michele L., primary, Chen, Sheau-Chiann, additional, Stricker, Thomas, additional, Hyman, David M., additional, Blauvelt, Natalie, additional, Bedard, Philippe L., additional, Meric-Bernstam, Funda, additional, Punglia, Rinaa S., additional, Schrag, Deborah, additional, Lepisto, Eva M., additional, Andre, Fabrice, additional, Smyth, Lillian, additional, Dogan, Semih, additional, Yu, Celeste, additional, Wathoo, Chetna, additional, Levy, Mia, additional, Eli, Lisa D., additional, Xu, Feng, additional, Mann, Grace, additional, Lalani, Alshad S., additional, Ye, Fei, additional, Micheel, Christine M., additional, and Arnedos, Monica, additional

Published
2022
Full Text
View/download PDF

14. Phase 1/2a, open‐label, multicenter study ofRM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma

Author

Cognetti, David M., primary, Johnson, Jennifer M., additional, Curry, Joseph M., additional, Kochuparambil, Samith T., additional, McDonald, Darren, additional, Mott, Frank, additional, Fidler, Mary J., additional, Stenson, Kerstin, additional, Vasan, Nilesh R., additional, Razaq, Mohammad A., additional, Campana, John, additional, Ha, Patrick, additional, Mann, Grace, additional, Ishida, Kosuke, additional, Garcia‐Guzman, Miguel, additional, Biel, Merrill, additional, and Gillenwater, Ann M., additional

Published
2021
Full Text
View/download PDF

15. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, Jos, and Solit, David B.

Subjects
Genetic aspects, Health aspects, Cancer -- Genetic aspects, Phosphotransferases -- Health aspects, Gene mutation -- Health aspects
Abstract

Author(s): David M. Hyman (corresponding author) [1]; Sarina A. Piha-Paul [2]; Helen Won [1]; Jordi Rodon [3]; Cristina Saura [3]; Geoffrey I. Shapiro [4]; Dejan Juric [5]; David I. Quinn [...], Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, basket trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

Published
2018
Full Text
View/download PDF

16. Carbon-sulfur bond-forming reductive elimination involving sp-, sp2, and sp3-hybridized carbon. Mechanism, steric effects, and electronic effects on sulfide formation

Author

Mann, Grace, Baranano, David, Hartwig, John F., Rheingold, Arnold L., and Guzei, Ilia A.

Subjects
Palladium -- Research, Chemical bonds -- Analysis, Sulfides -- Research, Oxidation-reduction reaction -- Analysis, Elimination reactions -- Analysis, Coordination compounds -- Research, Chemistry
Abstract

The mechanism, electronic and steric effects of the reductive elimination of sulfides from palladium thiolato aryl complexes were described. Carbon-sulfur bond-forming reductive elimination was observed to be fastest from the alkenyl and aryl complexes, slower for alkynyl complexes and slowest for alkyl complexes. The findings suggest that reductive elimination is best promoted by palladium complexes with large bite angles, electron-rich thiolato ligands and electron-deficient carbon-bound ligands.

Published
1998

18. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M, Piha-Paul, Sarina A, Won, Helen H, Schram, Alison M, Saura, Cristina, Loi, Sherene, Lu, Janice, Shapiro, Geoffrey I, Juric, Dejan, Mayer, Ingrid A, Arteaga, Carlos L, de la Fuente, Macarena I, Brufksy, Adam M, Spanggaard, Iben, Mau-Sørensen, Morten, Arnedos, Monica, Moreno, Victor, Boni, Valentina, Sohn, Joohyuk, Schwartzberg, Lee S, Gonzàlez-Farré, Xavier, Cervantes, Andrés, Bidard, François-Clement, Gorelick, Alexander N, Lanman, Richard B, Nagy, Rebecca J, Ulaner, Gary A, Chandarlapaty, Sarat, Jhaveri, Komal, Gavrila, Elena I, Zimel, Catherine, Selcuklu, S Duygu, Melcer, Myra, Samoila, Aliaksandra, Cai, Yanyan, Scaltriti, Maurizio, Mann, Grace, Xu, Feng, Eli, Lisa D, Dujka, Melanie, Lalani, Alshad S, Bryce, Richard, Baselga, José, Taylor, Barry S, Solit, David B, Meric-Bernstam, Funda, Hyman, David M, Smyth, Lillian M, Piha-Paul, Sarina A, Won, Helen H, Schram, Alison M, Saura, Cristina, Loi, Sherene, Lu, Janice, Shapiro, Geoffrey I, Juric, Dejan, Mayer, Ingrid A, Arteaga, Carlos L, de la Fuente, Macarena I, Brufksy, Adam M, Spanggaard, Iben, Mau-Sørensen, Morten, Arnedos, Monica, Moreno, Victor, Boni, Valentina, Sohn, Joohyuk, Schwartzberg, Lee S, Gonzàlez-Farré, Xavier, Cervantes, Andrés, Bidard, François-Clement, Gorelick, Alexander N, Lanman, Richard B, Nagy, Rebecca J, Ulaner, Gary A, Chandarlapaty, Sarat, Jhaveri, Komal, Gavrila, Elena I, Zimel, Catherine, Selcuklu, S Duygu, Melcer, Myra, Samoila, Aliaksandra, Cai, Yanyan, Scaltriti, Maurizio, Mann, Grace, Xu, Feng, Eli, Lisa D, Dujka, Melanie, Lalani, Alshad S, Bryce, Richard, Baselga, José, Taylor, Barry S, Solit, David B, Meric-Bernstam, Funda, and Hyman, David M

Abstract

HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with HER2-mutant metastatic breast cancer. Overall response rate was similar with or without estrogen receptor (ER) blockade. By comparison, progression-free survival and duration of response appeared longer in ER+ patients receiving combination therapy, although the study was not designed for direct comparison. Preexistent concurrent activating HER2 or HER3 alterations were associated with poor treatment outcome. Similarly, acquisition of multiple HER2-activating events, as well as gatekeeper alterations, were observed at disease progression in a high proportion of patients deriving clinical benefit from neratinib. Collectively, these data define HER2 mutations as a therapeutic target in breast cancer and suggest that coexistence of additional HER signaling alterations may promote both de novo and acquired resistance to neratinib. SIGNIFICANCE: HER2 mutations define a targetable breast cancer subset, although sensitivity to irreversible HER kinase inhibition appears to be modified by the presence of concurrent activating genomic events in the pathway. These findings have implications for potential future combinatorial approaches and broader therapeutic development for this genomically defined subset of breast cancer.This article is highlighted in the In This Issue feature, p. 161.

Published
2020

19. Phase 1/2a, open‐label, multicenter study of RM‐1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma.

Author

Cognetti, David M., Johnson, Jennifer M., Curry, Joseph M., Kochuparambil, Samith T., McDonald, Darren, Mott, Frank, Fidler, Mary J., Stenson, Kerstin, Vasan, Nilesh R., Razaq, Mohammad A., Campana, John, Ha, Patrick, Mann, Grace, Ishida, Kosuke, Garcia‐Guzman, Miguel, Biel, Merrill, and Gillenwater, Ann M.

Subjects
SQUAMOUS cell carcinoma, OVERALL survival, SURVIVAL rate, NECK
Abstract

Background: Recurrent head and neck squamous cell carcinoma (rHNSCC) represents a significant global health burden with an unmet medical need. In this study we determined the safety and efficacy of RM‐1929 photoimmunotherapy in patients with heavily pretreated rHNSCC. Methods: RM‐1929 (anti‐EGFR–IR700 dye conjugate) was infused, followed by tumor illumination. We evaluated safety, tumor response, and pharmacokinetics. Results: Nine patients were enrolled in Part 1 (dose‐finding) and 30 patients in Part 2 (safety and efficacy). No dose‐limiting toxicities were experienced in Part 1; 640 mg/m2 with fixed light dose (50 J/cm2 or 100 J/cm) was recommended for Part 2. Adverse events (AEs) in Part 2 were mostly mild to moderate but 19 (63.3%) patients had AE ≥Grade 3, including 3 (10.0%) with serious AEs leading to death (not treatment related). Efficacy in Part 2: unconfirmed objective response rate (ORR) 43.3% (95% CI 25.46%–62.57%); confirmed ORR 26.7% (95% CI 12.28%–45.89%); median overall survival 9.30 months (95% CI 5.16–16.92 months). Conclusions: Treatment was well tolerated. Responses and survival following RM‐1929 photoimmunotherapy in heavily pretreated patients with rHNSCC were clinically meaningful and warrant further investigation. Clinical Trial Information: NCT02422979. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., additional, Won, Helen H., additional, Schram, Alison M., additional, Saura, Cristina, additional, Loi, Sherene, additional, Lu, Janice, additional, Shapiro, Geoffrey I., additional, Juric, Dejan, additional, Mayer, Ingrid A., additional, Arteaga, Carlos L., additional, de la Fuente, Macarena I., additional, Brufksy, Adam M., additional, Spanggaard, Iben, additional, Mau-Sørensen, Morten, additional, Arnedos, Monica, additional, Moreno, Victor, additional, Boni, Valentina, additional, Sohn, Joohyuk, additional, Schwartzberg, Lee S., additional, Gonzàlez-Farré, Xavier, additional, Cervantes, Andrés, additional, Bidard, François-Clement, additional, Gorelick, Alexander N., additional, Lanman, Richard B., additional, Nagy, Rebecca J., additional, Ulaner, Gary A., additional, Chandarlapaty, Sarat, additional, Jhaveri, Komal, additional, Gavrila, Elena I., additional, Zimel, Catherine, additional, Selcuklu, S. Duygu, additional, Melcer, Myra, additional, Samoila, Aliaksandra, additional, Cai, Yanyan, additional, Scaltriti, Maurizio, additional, Mann, Grace, additional, Xu, Feng, additional, Eli, Lisa D., additional, Dujka, Melanie, additional, Lalani, Alshad S., additional, Bryce, Richard, additional, Baselga, José, additional, Taylor, Barry S., additional, Solit, David B., additional, Meric-Bernstam, Funda, additional, and Hyman, David M., additional

Published
2020
Full Text
View/download PDF

21. Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib

Author

Ulaner, Gary A., primary, Saura, Cristina, additional, Piha-Paul, Sarina A., additional, Mayer, Ingrid, additional, Quinn, David, additional, Jhaveri, Komal, additional, Stone, Ben, additional, Shahin, Seta, additional, Mann, Grace, additional, Dujka, Melanie, additional, Bryce, Richard, additional, Meric-Bernstam, Funda, additional, Solit, David B., additional, and Hyman, David M., additional

Published
2019
Full Text
View/download PDF

22. Abstract 4527: Patient-derived organoids and xenografts identify neratinib plus HER2 antibody drug conjugate as a synergistic drug combination for HER2 mutated, nonamplified metastatic breast cancer

Author

Li, Shunqiang, primary, Maureen, Highkin, additional, Primeau, Tina M., additional, Pratt, Stephanie L., additional, Diala, Irmina, additional, Cutler, Richard E., additional, Mann, Grace, additional, Lalani, Alshad S., additional, Ma, Cynthia X., additional, and Bose, Ron, additional

Published
2019
Full Text
View/download PDF

23. Identification, clinical-pathological characteristics and treatment outcomes of patients with metastatic breast cancer and somatic human epidermal growth factor receptor 2 (ERBB2) mutations

Author

Jongen, Lynn, primary, Floris, Giuseppe, additional, Boeckx, Bram, additional, Smeets, Dominiek, additional, Lambrechts, Diether, additional, Vander Borght, Sara, additional, Laenen, Annouschka, additional, Mann, Grace, additional, Cutler, Richard E., additional, Lalani, Alshad S., additional, Neven, Patrick, additional, and Wildiers, Hans, additional

Published
2018
Full Text
View/download PDF

24. Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study

Author

Hyman, David M., primary, Piha-Paul, Sarina A., additional, Rodon, Jordi, additional, Saura, Cristina, additional, Shapiro, Geoffrey I., additional, Quinn, David I., additional, Moreno, Victor, additional, Mayer, Ingrid A., additional, Arteaga, Carlos, additional, Boni, Valentina, additional, Calvo, Emiliano, additional, Loi, Sherene, additional, Lockhart, Albert C., additional, Smyth, Lillian M., additional, Erinjeri, Joseph, additional, Scaltriti, Maurizio, additional, Ulaner, Gary, additional, Torrisi, Jean, additional, Patel, Juber, additional, Tang, Jiabin, additional, Meng, Fanli, additional, Selcuklu, Duygu, additional, Won, Helen, additional, Bouvier, Nancy, additional, Berger, Michael F., additional, Cutler, Richard E., additional, Xu, Feng, additional, Butturini, Anna, additional, Eli, Lisa D., additional, Mann, Grace, additional, Lalani, Alshad S., additional, Bryce, Richard P., additional, Meric-Bernstam, Funda, additional, Baselga, José, additional, and Solit, David B., additional

Published
2017
Full Text
View/download PDF

25. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

Author

Forsyth, Timothy, Kearney, Patrick C., Kim, Byung Gyu, Johnson, Henry W.B., Aay, Naing, Arcalas, Arlyn, Brown, David S., Chan, Vicky, Chen, Jeff, Du, Hongwang, Epshteyn, Sergey, Galan, Adam A., Huynh, Tai P., Ibrahim, Mohamed A., Kane, Brian, Koltun, Elena S., Mann, Grace, Meyr, Lisa E., Lee, Matthew S., Lewis, Gary L., Noguchi, Robin T., Pack, Michael, Ridgway, Brian H., Shi, Xian, Takeuchi, Craig S., Zu, Peiwen, Leahy, James W., Nuss, John M., Aoyama, Ron, Engst, Stefan, Gendreau, Steven B., Kassees, Robert, Li, Jia, Lin, Shwu-Hwa, Martini, Jean-Francois, Stout, Thomas, Tong, Philip, Woolfrey, John, Zhang, Wentao, and Yu, Peiwen

Published
2012
Full Text
View/download PDF

27. Palladium-catalyzed C-O coupling involving unactivated aryl halides. Sterically induced reductive elimination to form the C-O bond in diaryl ethers

Author

Mann, Grace, Incarvito, Christopher, Rheingold, Arnold L., and Hartwig, John F.

Subjects
Palladium -- Research, Ethers -- Research, Elimination reactions -- Research, Chemistry
Abstract

Sterically hindered alkylphosphines in palladium complexes accelerate reductive elimination. Pd complexes with sterically hindered alkylphosphines undergo thermal reductive elimination to form the C-O bond in diaryl ethers from complexes with unactivated metal-bound aryl groups. They also serve as catalysts in the formation of diaryl ethers and protected phenols from unactivated aryl halides. Improvements in aryl halide etherification were sought using the ligand D'BPF (1,1'-bis(di-tert-butylphosphinoferrocene)).

Published
1999

28. Palladium-catalyzed C-N(sp2) bond formation: N-arylation of aromatic and unsaturated nitrogen and the reductive elimination chemistry of palladium azolyl and methyleneamido complexes

Author

Mann, Grace, Hartwig, John F., Driver, Michael S., and Fernandez-Rivas, Carolina

Subjects
Palladium catalysts -- Research, Organometallic chemistry -- Research, Chemical bonds -- Research, Chemistry
Abstract

A study was conducted on a general palladium-catalyzed arylation of azoles and imines using DPPF-ligated palladium and on C-N bond-forming reductive eliminations involving unsaturated or aromatic nitrogen. The findings indicate that the combination of Pd(OAc)2 and DPPF catalyzed the formation of N-aryl azoles in the presence of CS2CO3 or NaO-t-Bu with aryl halides. The results also suggest the possibility that the nucleophilicity of the nitrogen electron pair is a key factor in dictating reaction rates.

Published
1998

29. Palladium alkoxides: potential intermediacy in catalytic amination, reductive elimination of ethers, and catalytic etheration. Comments on alcohol elimination from Ir(III)

Author

Mann, Grace and Hartwig, John F.

Subjects
Palladium -- Research, Metal catalysts -- Research, Ether -- Research, Alcohol -- Research, Iridium -- Research, Chemistry
Abstract

A palladium aryl alkoxo complex was isolated. Arylamines were formed by reaction of this complex with HNRR' and aryl ethers were reductively eliminated from an analog of this complex with an electron deficient aryl group. Also, alkyl aryl ethers with DPPF-ligated palladium, most likely by C-O bond-forming reductive elimination, have been catalytically formed. The stability of an Ir(III) alkyl hydroxo complex previously reported to eliminate alcohol thermally has been investigated.

Published
1996

30. Phase I dose escalation trial of MVA-BN-PRO in men with nonmetastatic castration-resistant prostate cancer.

Author

McLeod, David G., primary, Adams, George W., additional, Gittleman, Marc C., additional, Bihartz, David L., additional, Reiling, Richard B., additional, Ruiz, Henry E., additional, Cochran, James S., additional, Prettyman, Julie, additional, Delcayre, Alain, additional, Godfrey, Wayne R., additional, Legrand, Fatema A., additional, Mann, Grace, additional, and Bandman, Olga, additional

Published
2013
Full Text
View/download PDF

46. Oral history interview with Grace Mann

Author

Mullen, Dennis, Freidman, Jeff, Mann, Grace, Mullen, Dennis, Freidman, Jeff, and Mann, Grace

Abstract

Mann studied ballet with Theodore Kosloff, Alexandra Baldina, Lew Christensen, Willam Christensen, and others. She toured with Ballet Russe in Europe. She returned to California and founded Ballet Valmann. Mann taught ballet until her retirement in 1992., Interview conducted for the Legacy Oral History Project., California Preservation Service (CAPS)

Catalog

Books, media, physical & digital resources
See catalog results